Related Experiment Videos
[Glimepiride--an oral antidiabetic agent]
Fahir Becić1, Elvedina Kapić, Ervina Becić
1Institut za farmakologiju, Klinicku Farmakologiju i toksikologiju, Medicinski fakultet Univerziteta u Sarajevu.
Medicinski Arhiv
|June 26, 2003
Summary
Glimepiride is a second-generation sulfonylurea effective for type II diabetes. It offers potent, long-lasting glucose reduction with a low risk of adverse effects, making it a preferred treatment option.
Area of Science:
- Pharmacology
- Endocrinology
Context:
- Glimepiride is an oral antidiabetic medication.
- It belongs to the second-generation sulfonylurea class.
- Structurally similar to glyburide, it offers improved efficacy.
Purpose:
- To evaluate the glucose-lowering effects and safety profile of glimepiride.
- To establish glimepiride's role in managing type II diabetes mellitus.
Summary:
- Glimepiride demonstrates more potent and longer-lasting glucose-lowering effects compared to glyburide.
- It stimulates insulin release from pancreatic beta cells in a dose-dependent manner (1-8 mg daily).
- Effective in reducing both fasting and postprandial blood glucose and glycosylated hemoglobin levels.
Impact:
- Glimepiride is a valuable adjunct to diet and exercise for type II diabetes.
- It offers a favorable safety profile with rare adverse effects and a low risk of hypoglycemia.
- Considered a preferable therapeutic option over glibenclamide due to its safety and efficacy.